Helen Davis

Hoverfly's integration with AeroVironment's AV_Halo isn't just a software update; it's a look into the future of networked warfare and market strategy.

With SMBs facing record premium hikes, Angle Health has raised $134M to scale its AI platform, promising to reshape benefits with lower costs and personalization.

A landmark study reveals only 13% of high-risk heart patients achieve optimal cholesterol control, exposing deep systemic failures and inequities in care.

With its lead cancer therapy on a fast track, March Biosciences taps a veteran dealmaker, signaling a strategic shift from clinical development to market play.

Actor Neal McDonough isn't just endorsing a wellness brand; he's on its leadership team. We analyze the market shift and what it means for consumers.

A new high-level panel, backed by major foundations and governments, launches a strategic, evidence-based plan to prevent gender-based violence at its roots.

Bayview's acquisition of Guild Mortgage isn't just a deal; it's the creation of a new powerhouse, fusing origination and servicing. What's next?

With cash reserves falling, Falcon's future hinges on a pivotal merger with Tamboran to create a dominant force in Australia's critical Beetaloo gas basin.

With a looming deadline and 13 new resorts, Alterra's Ikon Pass is escalating its global battle with Epic Pass for skier loyalty and market dominance.

PMI U.S. touts its $35M in community giving. But can corporate generosity escape the shadow of the tobacco industry? A deep dive into a complex issue.

A new survey on luxury property reveals an overlooked trend: an influx of affluent, middle-aged buyers poised to reshape Greece's private healthcare market.

Warner Music Group's landmark deal with AI leader Suno settles a lawsuit and sets a new precedent for artist control and monetization in music's AI era.

Just two months after a splashy IPO, StubHub faces a class-action lawsuit over alleged misleading financial reports, sending its stock tumbling.

With impressive Phase 2 results showing significant weight loss and A1c reduction, Novo Nordisk's amycretin is poised to challenge market leaders.

Facing market headwinds, consultancy Next 15 is betting on a radical overhaul. We analyze its AI pivot, strategic disposals, and path to future growth.

Paratus AMC's early call on mortgage-backed notes sends ripples through structured finance, forcing investors to grapple with reinvestment risk.

A routine filing reveals Eutelsat's radical transformation. The satellite giant is betting its future on a hybrid orbit strategy to power the world.

Beyond the music, Zach Bryan's massive 2026 tour with AEG Presents reveals a powerful new blueprint for market dominance in live entertainment.

Pluxee's recent share repurchase is more than a financial footnote. It's a telling indicator of management's confidence in the booming corporate wellness market.

Bruker acquires AST Revolution, a firm born from bankruptcy just 3 months ago. This is a story of a swift PE exit and a major bet on fighting superbugs.